Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL1 and CD38 Dual-Target CAR-T in r/r AML
NCT06880354Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1 and CD38 dual-target CAR-T cell injection in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity Rate at 28 days and Adverse Events at 96 weeks. Started May 2025; status: recruiting.
02
Drugs
CLL1 and CD38 dual-target CAR-T cell injection
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06880354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880354.